EZH2 and prostate carcinoma: Therefore, we initially compared the expression level of EZH2 and G9a in noncancerous mammary epithelial cells (MCF10A) and multiple cell lines from breast cancer (MCF7, BT549, and MDA-MB-231), colon cancer (SW480 and HCT116), and prostate cancer (PC3 and DU145).